References

High sensitivity, increased specificity, and improved precision
for accurate prediction of recurrence and better stratification
of patients with improved PFS over genomic-only methods1,2

Enhanced Performance

Rapid Turnaround Time

9-day average turnaround time for MRD in the clinical setting3

MRD, minimal residual disease; PFS, progression-free survival.

QUANTIFY CANCER

Guardant Infinity enables liquid-only MRD and response monitoring that is accessible and scalable across clinical trials.

Tissue-Free Sampling

A simple blood draw making it significantly easier to acquire, enabling a higher evaluable rate for clinical studies